Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to Earnings
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

Drugs Made In America Acquisition (DMAA) Enterprise Value (2025 - 2026)

Drugs Made In America Acquisition filings provide 2 years of Enterprise Value readings, the most recent being -$6137.0 for Q4 2025.

  • Quarterly Enterprise Value fell 354.26% to -$6137.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$6137.0 through Dec 2025, down 354.26% year-over-year, with the annual reading at -$6137.0 for FY2025, 354.26% down from the prior year.
  • Enterprise Value hit -$6137.0 in Q4 2025 for Drugs Made In America Acquisition, down from -$717.0 in the prior quarter.
  • Across five years, Enterprise Value topped out at -$717.0 in Q3 2025 and bottomed at -$6137.0 in Q4 2025.